| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7cc315cc5a1fe3bf4c1730dd5a48c1f2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-815 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-84 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate |
2021-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecced4b2a9358c5f3654d199a8cff9ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa722db60f173ee67af60528daa6e4c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_959ab036e89e5262294bdd1feeff5211
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67fdd84996dd42fb32aaa80d88076bd2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0194f4e2c2b6b26cbda3069d7abd2ebd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe2824b5ecb40c8985bd2283b6b4b3e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b391cda688fb16d2054e2da7e280eeb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc1d0612a68e058033df27f7372aa11a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdab24f8fe6d527afdf6b6f82d0fc68e |
| publicationDate |
2022-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-115160414-A |
| titleOfInvention |
Construction method of SARS-CoV-2 South African V2 mutant strain S protein receptor binding region-producing bacteria and its application |
| abstract |
The present invention discloses a method for constructing a SARS-CoV-2 mutant strain S protein receptor binding region producing bacteria, and the constructed production bacteria can realize the S protein receptor binding region of coronavirus SARS-CoV-2 South Africa V2 mutant strain It is highly expressed in Pichia pastoris cells, and has the characteristics of fast growth, easy large-scale production and high safety. The recombinantly expressed coronavirus SARS-CoV-2 South Africa V2 mutant strain does not have excessive glycosylation in the receptor binding region of the S protein, and it can produce high titers of anti-SARS-CoV-2 South Africa after immunizing mice with it Antibodies against the receptor binding region of the S protein of the V2 mutant strain, and can neutralize the SARS-CoV-2 mutant virus. Therefore, under emergency conditions such as new mutant coronavirus infection, it is conducive to the efficient development and large-scale production of new mutant coronavirus vaccines. |
| priorityDate |
2021-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |